These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 39349713)

  • 21. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
    Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
    Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
    Haggiagi A; Lassman AB
    Neuro Oncol; 2020 Aug; 22(8):1058-1059. PubMed ID: 32479605
    [No Abstract]   [Full Text] [Related]  

  • 23. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
    Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
    J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide.
    Quan R; Zhang H; Li Z; Li X
    Medicine (Baltimore); 2020 Jan; 99(2):e18591. PubMed ID: 31914038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and Future Drug Treatments for Glioblastomas.
    Ohba S; Hirose Y
    Curr Med Chem; 2016; 23(38):4309-4316. PubMed ID: 27758718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
    Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.
    Waschke A; Arefian H; Walter J; Hartmann M; Maschmann J; Kalff R
    J Neurooncol; 2018 Jun; 138(2):359-367. PubMed ID: 29468446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic.
    Kamson DO; Grossman SA
    JAMA Oncol; 2021 May; 7(5):675-676. PubMed ID: 33475680
    [No Abstract]   [Full Text] [Related]  

  • 30. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
    Chinot OL; de La Motte Rouge T; Moore N; Zeaiter A; Das A; Phillips H; Modrusan Z; Cloughesy T
    Adv Ther; 2011 Apr; 28(4):334-40. PubMed ID: 21432029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients.
    Lee IY; Hanft S; Schulder M; Judy KD; Wong ET; Elder JB; Evans LT; Zuccarello M; Wu J; Aulakh S; Agarwal V; Ramakrishna R; Gill BJ; Quiñones-Hinojosa A; Brennan C; Zacharia BE; Silva Correia CE; Diwanji M; Pennock GK; Scott C; Perez-Olle R; Andrews DW; Boockvar JA
    Future Oncol; 2024 Mar; 20(10):579-591. PubMed ID: 38060340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 (MACS study).
    Kadota T; Saito R; Kumabe T; Mizusawa J; Katayama H; Sumi M; Igaki H; Kinoshita M; Komori T; Ichimura K; Narita Y; Nishikawa R
    Jpn J Clin Oncol; 2019 Dec; 49(12):1172-1175. PubMed ID: 31804699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress and prospect in tumor treating fields treatment of glioblastoma.
    Liu S; Shi W; Zhao Q; Zheng Z; Liu Z; Meng L; Dong L; Jiang X
    Biomed Pharmacother; 2021 Sep; 141():111810. PubMed ID: 34214730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
    Carter TC; Medina-Flores R; Lawler BE
    Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
    Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
    Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioblastoma and bevacizumab in elderly patients: Monocentric study.
    Barrascout E; Lamuraglia M
    J Oncol Pharm Pract; 2021 Jun; 27(4):842-846. PubMed ID: 32660379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab.
    Papageorgiou GI; Tsakatikas SA; Fioretzaki RG; Kosmas C
    Anticancer Drugs; 2021 Mar; 32(3):330-336. PubMed ID: 33229903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.
    Minniti G; De Sanctis V; Muni R; Filippone F; Bozzao A; Valeriani M; Osti MF; De Paula U; Lanzetta G; Tombolini V; Maurizi Enrici R
    J Neurooncol; 2008 May; 88(1):97-103. PubMed ID: 18250965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.
    Seystahl K; Hentschel B; Loew S; Gramatzki D; Felsberg J; Herrlinger U; Westphal M; Schackert G; Thon N; Tatagiba M; Pietsch T; Reifenberger G; Löffler M; Wick W; Weller M;
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):659-670. PubMed ID: 31754832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.